• Balchem highlighted clinical research supporting OptiMSM for adults with mild knee discomfort, with results already presented as research findings.
• Study outcome showed improved knee-related quality of life, better perceived knee comfort, improved overall health perceptions.
• Findings position OptiMSM as evidence-backed ingredient for joint health, supporting product marketing and portfolio differentiation in supplement category.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Balchem Corporation published the original content used to generate this news brief on May 08, 2026, and is solely responsible for the information contained therein.